Geographies covered
Global Genomic Biomarker Market – Regional Analysis
On the basis of region, the global genomic biomarker market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global genomic biomarker market over the forecast period, owing to involvement of market players in inorganic market strategies such as collaborations, partnerships, acquisitions, and others. For instance, in August 2020, GeneCentric Therapeutics Inc., an American genomic technology provider, announced its collaboration with Janssen Research & Development, LLC (an American pharmaceutical company) to develop a novel non-invasive RNA-based genomic biomarker for the diagnosis of bladder cancer.
Key players are focused on launching new products and receiving approvals (from regulatory bodies) for their products indicated for diagnosis of various diseases such as cancer, stroke, and arthritis, which is expected to drive growth of the market in North America and Europe. For instance, in May 2021, Qiagen, a German molecular diagnostic technology provider, launched its first U.S FDA approved diagnostic kit for the detection of KRAS mutations in non-small cell lung cancer (NSCLC) patients. KRAS mutations act as a genomic biomarker for cancer detection and also help in checking the eligibility of patients for undergoing treatment therapy with a newly developed Lumakras therapy developed by Amgen Inc.
Genomic Biomarker Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients